The U.S. FDA has
altered clinical laboratory staff of a risk of false results with ThermoFisher’s
TaqPath COVID-19 Combo Kit. Thus is linked with two issues related to the test
kit (imprecise instructions on sample preparation for the PCR plates and a
concern with the positive contort); and one issue related to the Applied
Biosystems COVID-19 Interpretive Software used to produce the test results.
TaqPath was fast tracked by the FDA and in Europe in March 2020.
Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)
No comments:
Post a Comment
Pharmaceutical Microbiology Resources